ruxolitinib
Brand: RUXOLITINIB
Quick answer
ruxolitinib (RUXOLITINIB), is a pharmaceutical active ingredient, with approved status in the US.
Key facts
- INN
- ruxolitinib
- Brand
- RUXOLITINIB
- Route
- ORAL
- Formulation
- TABLET
Related news
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders
Incyte receives FDA approval for once-daily Jakafi XR (ruxolitinib) extended-release tablets for myelofibrosis, polycythemia vera, and GVHD treatment.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment
Incyte receives FDA approval for Jakafi XR (ruxolitinib) extended-release tablets, offering improved dosing convenience for rare blood cancer patients.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera, and GVHD Treatment
Incyte receives FDA approval for Jakafi XR (ruxolitinib) extended-release tablets, offering improved dosing convenience for rare blood disorders and GVHD patients.
Frequently asked questions
What is ruxolitinib?
ruxolitinib (RUXOLITINIB), is a pharmaceutical active ingredient, with approved status in the US.
What is the brand name for ruxolitinib?
RUXOLITINIB is a marketed brand name for ruxolitinib. Check FDA Drugs@FDA for the current US label holder.